Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.

Takeda Pharmaceutical Company Ltd (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha) is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following merger with Shire). The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.

Provides research and consulting services for small and medium-sized companies

Manufactures, marketes and imports, exports pharmaceutical drugs

Schering Corp. manufactures pharmaceutical products. It offers products in the areas of allergy and respiratory, anti-infectives, foot care, hepatitis, skin disorders, and sun care. It is a subsidiary of Schering-Plough Corp. The company is headquartered in Kenilworth, NY.

Rechon Life Science AB manufactures medicines. It specializes in aseptic injectables and sprays for nasal and oral administration. The firm's products include Iron Sucrose Injection. The firm's services include formulation and analytical development, clinical trial, stability studies, and storage and distritutions. The company is headquartered in Limhamn, Sweden.

Tianjin Medical University Cancer Institute and Hospital (TMUCIH) is the birthplace of oncology in China. It has developed into one of the largest cancer centers in China.

SBI Biotech mainly focuses on dendritic cell platform-based innovative drug development. As an R&D-type bio-venture company, we do not have abundant human resource like in the case of general pharmaceutical companies and we mainly focus on our activity in the early stages of drug development. Particularly, our biggest hurdle is the clinical studies / clincal trials which we need huge budgets to support our clinical trials on human to test drug safety and efficacy. We have been trying to utilize our human and financial resources efficiently by early licensing of our pipelines in the preclinical stage, instead of performing the clinical trials by our own. For the early stage licensing, we have tried to provide excellent products by the world-leading research team with the expertise in dendritic cell manipulation. We have successfully proven the feasibility of the business model since we succeeded in licensing of our early stage dendritic cells targeting antibody, anti-ILT7 antibody to MedImmune. We will continue our efforts in early licensing activity by our highly competitive research team.

Guangdong Ruiqi Biotechnology Co., Ltd., established on 2017-05-12, The scope of business includes engaging in biotechnology,Technology research and development in the field of medical equipment and computer software,technical consulting,Technical Services,technology transfer;wholesale,retail:medical supplies,medical instruments,Laboratory equipment and scientific research products(Operating with a valid operating license);Import and export,Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Baygate Biotechnology (Shanghai) Co., Ltd., established on 2016-04-20, Business scope includes licensed projects:Import and export;Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments) General project:engaged in biotechnology,Technology development in the field of network technology,technical consulting,technology transfer,Technical Services,internet sales(Except for products that require a license for sale),Nutrition and Health Consulting Services,Information Consulting Service(Not including licensing information consulting services),Catering Business Management,Conference and Exhibition Services,Etiquette service,Daily necessities,Hotel Supplies,kitchen equipment,Sales of laboratory equipment,Chemical product sales(No licensed chemical products).(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Shandong CliniSciences Biotech Co., Ltd. engages in the research, development, production and sale of in vitro diagnostic products and biochemical raw materials. Its products include biochemical diagnostic reagents and biochemical analyzers. The company was founded on May 28, 2004 and is headquartered in Linyi, China.

IMMUNSYSTEM was founded in 1983 by Anders Larsson from Uppsala University and Per-Erik Wejåker from the Swedish University of Agriculture. The researchers brought together the disciplines of protein research and animal handling. Much of their work was done in the production and use of antibodies within diagnostics. Over the years, inherent advantages were found with avian antibodies (IgY) and the focus of the company shifted towards using IgY. During the following years, IMMUNSYSTEM developed kits for screening of specific analytes and offered a large selection of purified antibodies for use in diagnostics.

Engages in research and development of biological products

Green Cross Co., Ltd. engages in the manufacture, sale, and rental of safety items. Its products include road safety materials, disaster prevention necessities, safety equipment, protection gear, and signboards and tags. The company was founded in January 1969 and is headquartered in Fukuoka, Japan.

Eiken Chemical Co., Ltd. engages in the manufacture and sale of clinical diagnostics products and equipment. It operates through following business divisions: Clinical Diagnostics and Testing of Food and Environment. The Clinical Diagnostics division handles the manufacture of clinical diagnostic products and services. The Testing of Food and Environment division deals with the sale of reagents for microbiological tests on food for poisoning bacteria, and environment for contamination of work environments. Its products include fecal immunochemical testing equipment, molecular test loop-mediated isothermal amplification (LAMP), immunological and serological reagents, and rapid diagnostic tests such as IMMUNOCATCH Norovirus, IMMUNOCATCH Legionella, and IMMUNOCATCH Streptococcus pneumoniae. The company was founded on February 20, 1939 and is headquartered in Tokyo, Japan.

Fastilium Property Group AB engages in the development and management of residential and commercial properties. The company was founded on June 7, 2006 and is headquartered in Stockholm, Sweden.

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.